Dr. Miano is a Critical Care Pharmacist and pharmacoepidemiologist who has dedicated his career to improving the safety and effectiveness of pharmacotherapy in acutely ill patients. He is an elected fellow of the American College of Critical Care Medicine and an Executive Editor of the British Journal of Clinical Pharmacology.

Dr. Miano’s federally funded research program leverages electronic health record data to study three critically important areas within acute-care pharmacoepidemiology: drug associated acute kidney injury (AKI), anticoagulation safety and comparative effectiveness, and the health effects of drug interactions. He has gained a national reputation for this expertise and has given multiple invited lectures on these topics. His lab was the first to show that kidney disease strongly modifies the severity of drug-drug interactions, a finding that has mechanistic implications for dozens of drug combinations commonly encountered in clinical practice.

His work has also advanced our understanding of the limitations of current phenotyping methods for drug-associated AKI. He recently led a study that measured cystatin C, a novel biomarker of kidney function, to show how AKI phenotypes based on creatinine, the standard AKI biomarker, can lead to spurious AKI signals for specific drug combinations. This work questions the results of dozens of prior creatinine-based studies and stands to establish a new paradigm for evaluating drug-associated AKI.